In this image courtesy of the Henry Ford Health System, volunteers are given the Moderna mRNA-1273 Coronavirus Efficacy (COVE), on August 5, 2020, in Detroit, Michigan. - The first COVID-19 vaccine trial volunteers in Michigan received their first shots Augus 5, in an effort to help find a safe, effective vaccine to the deadly coronavirus. This is a historic moment, said Dr. Marcus Zervos, Division Chief of Infectious Disease for Henry Ford Health System. A vaccine is our best hope in the fight against COVID-19, and were glad to be a part of bringing this opportunity to the Midwest. (Photo by - / Henry Ford Health System / AFP) / RESTRICTED TO EDITORIAL USE - MANDATORY CREDIT "AFP PHOTO / Henry Ford Health System" - NO MARKETING - NO ADVERTISING CAMPAIGNS - DISTRIBUTED AS A SERVICE TO CLIENTS (Photo by -/Henry Ford Health System/AFP via Getty Images)
Multiple potential vaccines in critical phase three trial
03:23 - Source: CNN
CNN  — 

Nine vaccine makers say they have signed a joint pledge to uphold “high ethical standards,” suggesting they won’t seek premature government approval for any Covid-19 vaccines they develop.

“We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles,” the pledge, released Tuesday, reads.

The companies that signed the pledge include AstraZeneca, BioNTech, Moderna, Pfizer, Novavax, Sanofi, GlaxoSmithKline, Johnson & Johnson and Merck.

President Trump has repeatedly pushed for a quick vaccine timeline – even referencing Election Day in November.

“[It’s] going to be done in a very short period of time – could even have it during the month of October,” the President said at a press briefing on Monday. “We’ll have the vaccine soon, maybe before a special date. You know what date I’m talking about.”

On August 6, Trump said he was “optimistic” a vaccine would be ready by November 3. This has caused widespread worry that the federal government might rush a vaccine to market before it has been adequately tested.

And late last month, US Food and Drug Administration Commissioner Dr. Stephen Hahn said in an interview with the Financial Times that the agency could consider emergency use authorization or approval for a Covid-19 vaccine before critical Phase 3 trials are complete.

The nine companies on Tuesday wrote that they pledge to “Only submit for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA.”

There are caveats in the pledge. At the bottom of a news release about the pledge, the companies mention “risks and uncertainties” that could cause some different results in the future.

“These risks and uncertainties include, but are not limited to: competition to create a vaccine for COVID-19; the ability to produce comparable clinical results in larger and more diverse clinical trials; the ability to effectively scale our productions capabilities; and other potential difficulties,” BioNTech said in one statement.